Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

2024 Corporate Membership Program 1 Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $20,000 Limited to three (3) companies per State Society first come, first served $14,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One (1) dedicated stand-alone e-blast to …
2024 Corporate Membership Program 1 Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $20,000 Limited to three (3) companies per State Society first come, first served $14,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One (1) dedicated stand-alone e-blast to …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TxSCO ONCOLOGY DRUG NEWSLETTER M AY 2 0 2 4 FDA APPROVALS Idecabtagene vicleucel (ide-cel, Abecma) Idecabtagene vicleucel (ide-cel, Abecma) has been approved by the FDA for the treatment of patients with relapsed or refractory …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. NCOA ONCOLOGY DRUG NEWSLETTER M A R C H 2 0 2 4 FDA APPROVALS Axicabtagene Ciloleucel (Axi-Cel; Yescarta) The FDA has approved a manufacturing process change resulting in a shorter manufacturing time for axicabtagene ciloleucel …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TxSCO ONCOLOGY DRUG NEWSLETTER M A R C H 2 0 2 4 FDA APPROVALS Axicabtagene Ciloleucel (Axi-Cel; Yescarta) The FDA has approved a manufacturing process change resulting in a shorter manufacturing time for axicabtagene ciloleucel …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TACOS ONCOLOGY DRUG NEWSLETTER M A R C H 2 0 2 4 FDA APPROVALS Axicabtagene Ciloleucel (Axi-Cel; Yescarta) The FDA has approved a manufacturing process change resulting in a shorter manufacturing time for axicabtagene ciloleucel …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. SCOS ONCOLOGY DRUG NEWSLETTER M A R C H 2 0 2 4 FDA APPROVALS Axicabtagene Ciloleucel (Axi-Cel; Yescarta) The FDA has approved a manufacturing process change resulting in a shorter manufacturing time for axicabtagene ciloleucel …
LIO-Legislative-Town-Hall-3.22.22 Leaders in Oncology Legislative Town Hall March 22, 2022 Meeting Recording: https://zoom.us/rec/share/ gz7cHJssXRDK1EPwuPODdCxt1Ss58HwRejhwvkCc7yO TB6lS08_aSKI0G7j5_RS6.o8JdTZIkuvwa2LVW Access Passcode: &57cySt. Note - Include the period at the end of password Discussion Highlights are included in the Notes Section of each slide …
VTB-ACCC-Molecular-Testing-Article
Facility Design & Construction Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Facility Design & Construction Brian Campbell & Mandy Gries To cite this article: Brian Campbell & …
A Comparative Report on Key Cancer DRGs Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 A Comparative Report on Key Cancer DRGs Lee E. Mortenson & Mary Lou Bowers To cite this …
1 The Association of Community Cancer Centers (ACCC) developed this checklist to help cancer practices and programs adopt the use of bispecific antibodies (BsAbs) to treat cancer. Community cancer providers may use this checklist whether their program is referring patients to academic centers or treating patients in-house. Users should refer to the section of the checklist that is pertinent to …
A Study of Patients in Cancer-Related DRGs A STUDY OF PATIENTS IN CANCER· RELATED DRGs Susan D. Horn, Ph.D. and Phoebe D. Sharkey, Ph.D. Center for Hospital Finance and Management The JohnsHopkins Medical Institutions ~ ABSTRACT .1" he DRGs representing lymphoma, leukemia, and other cancer-related diseases contain wide variations in patient severityofillnessand use …
Outpatient Cancer Visit Groups: A Preliminary Report on Work in Progress in Ontario, Canada Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Outpatient Cancer Visit Groups: A Preliminary …
A Study of Patients in Cancer-Related DRGs A STUDY OF PATIENTS IN CANCER· RELATED DRGs Susan D. Horn, Ph.D. and Phoebe D. Sharkey, Ph.D. Center for Hospital Finance and Management The JohnsHopkins Medical Institutions ~ ABSTRACT .1" he DRGs representing lymphoma, leukemia, and other cancer-related diseases contain wide variations in patient severityofillnessand use …
PowerPoint Presentation Community Oncology Alliance © www.CommunityOncology.org. |Community Oncology Alliance © www.CommunityOncology.org | James Lee Sr. Manager, State Regulation and Policy Community Oncology Alliance September 16, 2022 VAHO Leadership Day 2022 Legislative Update Community Oncology Alliance © www.CommunityOncology.org. |Community Oncology …
Conversation Guide: Biomarker Testing and its Role in Your Cancer Journey What biomarker testing is recommended for the specific type of cancer I have? Have any of these tests already been done? If so, what do they show? What steps do I need to take to get any additional recommended biomarker testing? How will the results be used to guide my cancer care? Who can I talk to if I have …
3/21/22, 3:48 PM AMCCBS > COVID-19 Health and Safety Protocols https://www.accc-cancer.org/home/attend/accc-48th-annual-meeting-cancer-center-business-summit/covid-19-health-and-safety-protocols/Action/Preview 1/2   Home / Attend / ACCC 48th Annual Meeting & Cancer Center Business Summit / COVID-19 Health and Safety Protocols COVID-19 Health and Safety Protocols We are thrilled …
Our two primary asks highlight legislation that would improve patient access to telehealth beyond the end of the COVID- 19 Public Health Emergency and reduce delays in cancer care due to prior authorization requirements in the Medicare Advantage (MA) program: 1. Cosponsor the Telehealth Modernization Act (H.R. 1332/S. 368)  To permanently expand access to Medicare telehealth services by removing …